News

MedPage Today1h
Win for Added Relacorilant in Platinum-Resistant Ovarian Cancer
In addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...
Healio2h
FDA expands darolutamide indication for advanced prostate cancer
The FDA has approved darolutamide without chemotherapy for treatment of metastatic hormone-sensitive prostate cancer.The FDA ...
Fierce Biotech3h
With BMS and Pfizer joining the PD-1 bispecific race, Lilly and Novartis size up the hot cancer field
As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...